Manchester scientists to receive £1.2million for new era in pancreatic cancer research
Manchester scientists are set to receive £1.2million from Cancer Research UK to help transform pancreatic cancer treatment in the UK.
Around 1,000 people are diagnosed with pancreatic cancer in the North West every year, and currently around 930 people die from the disease.
Scientists from the Cancer Research UK Manchester Institute, based at The University of Manchester, will work with experts at The Christie NHS Foundation Trust and with researchers across the UK on the project to develop new treatments for pancreatic cancer using a network of clinical trials, aiming to find the right trial for the right patient.
The project aims to speed up recruitment and enrolment of pancreatic cancer patients to clinical trials that are right for the individual patient, with patients being selected based on their individual tumour.
The researchers will use the molecular profile of each individual cancer to offer patients and their doctor a menu of trials that might benefit them.
Three initial trials planned as part of this initiative will recruit a total of 658 patients from a number of centres across the UK, with the scope to add more trials in the future. Patients may also be helped onto suitable clinical trials that are already up and running.
At The University of Manchester, Professor Juan Valle, an expert medical oncologist treating pancreatic cancer patients based at The Christie NHS Foundation Trust, said: “PRECISION Panc aims to transform how we treat pancreatic cancer by matching the right treatment to the right patient. Because the disease is so aggressive, patients may be too unwell and receive no treatment at all, or if they are given an option it may be for just one line of treatment, so it’s essential that the most suitable treatment is identified quickly. It’s important we offer all patients the opportunity to be part of research alongside their standard care. The Christie patients will be invited to participate into the multiple clinical trials developed within the PRECISION-Panc project, once they come on line.”
Professor Caroline Dive, Cancer Research UK Manchester Institute’s Deputy Director and an expert in so-called liquid biopsies, said: “Repeat tumour biopsies are challenging for pancreas cancer patients and my laboratory is very excited to be working with clinical colleagues to determine if measuring DNA shed from pancreas cancer tumours into the bloodstream can help us select treatments and monitor patients responses.”
Dr Claus Jorgensen, an expert in pancreas cancer biology at the Cancer Research UK Manchester Institute, said: “We aim to grow patient’s pancreas cancer cells in the laboratory and understand how different cells within a patient’s tumour interact with each other to promote growth and resistance to drugs, hence discovering new ways to attack pancreas cancer.”
All three researchers in Manchester agree that the Precision programme will ensure discoveries from the lab rapidly reach patients, and that data from clinical trials feed back into research of the disease.
Cancer Research UK’s investment will support two of the three clinical trials, preclinical work, assay development, biomarker work and the huge amount of molecular sequencing.
The charity’s funding will also provide overarching support though project management, funding staff, and a steering committee.
PRECISION Panc has been developed over the course of three years through the unwavering commitment of pancreatic clinicians and researchers who see that the patients deserve much more than is currently available to them.
Dr Ian Walker, Cancer Research UK’s director of clinical research, said: “This ambitious project marks a new era for pancreatic cancer. Little progress has been made in outcomes for pancreatic cancer patients over the last 40 years, and we believe that PRECISION Panc will reshape how we approach treatment development. Cancer Research UK is determined to streamline research, to find the right clinical trial for all pancreatic cancer patients and to ensure laboratory discoveries have patient benefit.”
Rachel Teale, 46, from Worsley, near Manchester, lost her father Bruce to pancreatic cancer in 2004 at the age of 62.
He had been diagnosed with pancreatic cancer a year earlier in November 2003 and had been treated at the Christie.
Rachel said: “It’s good to see such a big investment in pancreatic cancer research in the North West. My dad’s last 12 months were filled with pain. He was diagnosed the month my mum retired, and he never got to see his granddaughter, who he doted on, grow up and realise her dreams. We need more research to find better treatments so other people don’t have to go through what Dad went through, and so others can live to enjoy their retirement and see their grandchildren grow up.”